Siggy has launched an AI-enabled mental health service with US$6m in pre-seed funding, combining virtual therapy, prescription management and ongoing patient support.
The US startup has emerged from stealth with a platform designed to provide personalised mental healthcare through human clinicians and artificial intelligence.
The service combines therapy, medication management, AI-supported assessments and assistance between appointments.
Siggy co-founder and CEO Jonathan Sabbagh said: “It can build a really detailed picture of you rather fast, and the idea is if there are behaviour patterns that are recurrent.
“[Siggy can] begin to help people gain agency and recognise them before they happen.”
Patients begin with a free, anonymous conversation with Siggy’s AI system, without needing an account or login.
The platform retains information shared during the conversation so patients do not have to repeat their history when they meet a clinician.
The AI generates a preliminary diagnosis, which healthcare professionals review before presenting treatment options.
After speaking with a human provider, patients can log in to add existing healthcare professionals or relatives and confirm their treatment goals.
The initial assessment is free, with patients paying only if they choose to proceed with treatment.
Those accepting treatment see a human clinician monthly and can use Siggy’s AI between appointments.
The therapy AI agent draws on their history to help them work towards treatment goals, remember recommended exercises and discuss their experiences.
It does not answer medical questions, instead referring these to healthcare professionals. Safety protocols are also designed to identify patients requiring more intensive support and alert clinicians.
Siggy can connect with wearable devices and offers daily check-ins lasting approximately one minute.
Patients report on their sleep, mood, physical wellbeing and medication side effects.
The information is combined into a daily Siggy Score out of 100, which both patients and clinicians can view.
Siggy’s US$6m pre-seed funding was backed by Village Global and several angel investors.
The company says its service is covered by major commercial insurers across all 50 US states, including Blue Cross Blue Shield, Aetna, UnitedHealthcare and Humana.
It also accepts Medicaid, Medicare and TRICARE, and says its services are free for veterans.
Siggy can prescribe medications, excluding controlled substances. Clinicians can also gradually reduce doses when patients are ready to stop treatment.
Looking ahead, the company hopes to explore whether analysing speech, laboratory results, genetic testing and biological markers could help identify other conditions, including diabetes and amyotrophic lateral sclerosis (ALS).
It also wants to develop neural datasets to support clinical trials involving technologies such as brain implants.
